ROCKVILLE, Md., May 23, 2016 /PRNewswire/ -- Tomorrow, Immunomic Therapeutics,Inc. (ITI) CEO Bill Hearl, PhD and Oncosec Medical Senior Vice President David Meininger, PhD, MBA will host a fireside chat to discuss both the buy and sell side of pharmaceutical negotiations.
Who: Immunomic Therapeutics, Inc. CEO Bill Hearl, PhD and Oncosec Medical Senior Vice President David Meininger, PhD, MBA
What: Fireside chat, open to media and biotech and pharma executives.
When: May 24, 2016, 11:30 am ET.
Where: Bethesda North Marriott Hotel + Conference Center at 5701 Marinelli Rd, North Bethesda, MD 20852.
Follow the conversation on Twitter at #BT16CONF.
About ITIImmunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These disruptive technologies have the potential to fundamentally improve how we use immunotherapy for cancer, allergies and animal health. Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI has entered into a significant licensing agreement with Astellas Pharma Inc., to explore the use of LAMP-Vax, a next-generation immunotherapy platform, for use to prevent and treat allergic diseases. ITI believes that LAMP-based nucleic acid immunotherapy may have the potential to broaden the current use of cancer immunotherapy. Preclinical data is currently being developed to explore how LAMP nucleic acid constructs could both amplify and activate the immune response in highly immunogenic tumor types and also be used to create robust immune responses to tumor types that otherwise do not provoke an immune response. For information about ITI and LAMP technology, visit www.immunomix.com.
About OncoSec Medical IncorporatedOncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse™, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as interleukin-12 (IL-12). In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse™ IL-12 is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immunomix-ceo-and-oncosec-vp-to-host-fireside-chat-300272484.html
SOURCE Immunomic Therapeutics, Inc.
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All